Avicanna Announces Changes to its Board of Directors

Core Insights - Avicanna Inc. announces the resignation of Mr. Paul Fornazzari from its board of directors and the appointment of Mr. Michael Kott, effective January 1, 2026 [1][2] Group 1: Leadership Changes - Mr. Michael Kott brings over 35 years of experience in international capital markets, corporate finance, and fundraising, having founded CM-Equity AG, which transitioned into a global single-family office in 2025 [2] - Mr. Kott has a strong background in governance, compliance, capital markets transactions, IPOs, and cross-border investments, and is an active independent investor across various sectors including biopharma and technology [2] Group 2: Company Vision and Strategy - Mr. Kott expresses optimism about Avicanna's future, highlighting the company's position in the natural pharmaceuticals megatrend and the potential impact of recent communications from the White House regarding cannabis reclassification in the US [3] - The CEO of Avicanna, Aras Azadian, acknowledges Mr. Fornazzari's contributions and welcomes Mr. Kott, emphasizing the importance of his expertise in capital markets for the company's growth and shareholder value [4] Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing cannabinoid-based products for the global medical and pharmaceutical markets, with over thirty proprietary, evidence-based finished products [5] - The company operates a medical cannabis formulary (RHO Phyto™) and a medical cannabis care platform (MyMedi.ca), aimed at enhancing patient care and education [5] - Avicanna has a pharmaceutical pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [5]